Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Relapsed/Refractory) | Decision Base | US/EU | 2014

Login to access report north_east
Contact sales account_box

As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers?

The introduction of the anti-CD20 monoclonal antibody (MAb) rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo’s Rituxan/MabThera) profoundly revolutionized the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Although the MAbs alemtuzumab (Sanofi/Genzyme’s Campath/MabCampath) and ofatumumab (GlaxoSmithKline/Genmab’s Arzerra) have expanded treatment options for relapsed/refractory (R/R) CLL/SLL, this heterogenic patient population remains difficult to treat. The February 2014 approval of ibrutinib (Johnson & Johnson/Janssen/Pharmacyclics’ Imbruvica) represents a significant milestone in the treatment of R/R CLL and will serve to increase competition in the market. Nevertheless, significant clinical and commercial opportunity remains for therapies that can provide survival benefits greater than those of current standards of care.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east